NetworkNewsBreaks – Catabasis Pharmaceuticals (NASDAQ: CATB) Reports Positive Functional Assessment Results in MoveDMD® Trial for Edasalonexent in DMD
Catabasis Pharmaceuticals (NASDAQ: CATB) this morning reported positive results in the MoveDMD trial across multiple functional assessments, which were recently presented at the American Academy of Neurology 69th Annual Meeting. Numerical improvements were seen in prespecified rate change analyses across five functional assessments in part B of the trial, which was designed to evaluate the potential of edasalonexent in the treatment of Duchenne muscular dystrophy (DMD). These results are consistent with the numerical improvements in the same functional assessments with edasalonexent compared to placebo after 12 weeks of edasalonexent treatment. Part C interim results are anticipated for the third quarter…